In Amendment No. 1 to its Form 8-K/A filed on June 26, 2024, Medtronic said the Compensation Committee approved changes to the compensation arrangements for Gary Corona, its interim Chief Financial Officer, on August 15, 2024.

1. 01

   In Amendment No. 1 to its Form 8-K/A filed on June 26, 2024, Medtronic said the Compensation Committee approved changes to the compensation arrangements for Gary Corona, its interim Chief Financial Officer, on August 15, 2024.

2. 02

   The company said the Compensation Committee on August 15, 2024 approved for Gary Corona a bi-weekly cash stipend of $12,500, effective August 3, 2024, and a grant of 8,966 time-based restricted stock units (RSUs).

3. 03

   The company said the approved RSUs vest over 2 years, with 50% of the total shares vesting on each of the first and second anniversaries of the grant date.

4. 04

   The company said the Compensation Committee kept Gary Corona's annual base salary at $500,000, his target bonus at 70% of base salary, and his long-term incentive grant of $1 million awarded on July 29, 2024.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.